Pharmaceutical Preparations · SIC 2834

KAZIA THERAPEUTICS LTD

KZIA

Watch

Latest revenue

as of

Latest net income

as of

Net margin

as of

Price · 5Y

-51.0% / yr 64.7 pts / yr vs S&P 500 97.1% total
Compare:

Live market

delayed ≤15 min
$13.66
3.72%
Market cap
$11.06B
Enterprise value
$11.06B
P/E (trailing)
Forward P/E
P/B
Dividend yield
0.0%
52-wk high
$17.40
52-wk low
$3.41
Beta
Shares out
809.4M

5-year trend

No quarterly data ingested yet for this company.

About KZIA

Business description and risk factors will appear here once KZIA's latest filing is fully ingested.

Earnings tracker

Not enough quarterly history for KZIA yet to draw an earnings tracker.

Industry trend

Pharmaceutical Preparations · SIC 2834

No data yet for industry average

Your notes

Keep private notes on KZIA — thesis, target price, catalysts to watch.

Visible only to you. Never shared. Never used to train AI.

Sign in to write a note

Insider activity

No insider transactions on file for KZIA in the last 12 months.

Source: SEC Form 4 filings. Backfill runs nightly.

Who owns KZIA

Institutional value

$2.0M

Total shares held

280.9K

Distinct holders

8

-14 vs prior

As of

2026-03-31

Prior: 2025-12-31

Filers with $100M+ AUM disclose holdings 45 days after quarter end.

Top institutional holders

#ManagerSharesValueQoQ changeAction
1FLPUTNAM INVESTMENT MANAGEMENT CO142.5K$1.1MNew
2Sequoia Financial Advisors, LLC60.0K$446.4KNew
3Westside Investment Management, Inc.50.4K$375.2K+19.6K (+63.3%)Added
4UBS Group AG13.9K$103.7K+13.7K (+7119.7%)Added
5GAMMA Investing LLC1.6K$11.7K+1.3K (+575.9%)Added
6RHUMBLINE ADVISERS1.4K$10.4K-163 (-10.4%)Trimmed
7BNP PARIBAS FINANCIAL MARKETS1.1K$8.0KNew
8FNY Investment Advisers, LLC10.0K$74+2.5K (+33.3%)Added

Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.

Top questions investors are asking

Coming once KZIA's latest filing finishes processing.